Mayo Clinic Laboratory and Pathology Research Roundup: April 10

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Thyroid Hormone Treatment among Pregnant Women with Subclinical Hypothyroidism: U.S. National Assessment

Mayo Clinic researchers conducted a study to estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment thyroid stimulating hormone (TSH) concentration of 4.8 mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 mIU/L were not treated. Pregnancy loss was significantly less common among treated women than among untreated women. Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss but higher odds of preterm delivery, gestational diabetes, and pre-eclampsia; other pregnancy related adverse outcomes were similar between the two groups. Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population. The study was published in BMJ.

Published to PubMed This Week

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.